Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells

Christine Bangert,Natalia Alkon,Sumanth Chennareddy,Tamara Arnoldner,Jasmine P. Levine,Magdalena Pilz,Marco A. Medjimorec,John Ruggiero,Emry R. Cohenour,Constanze Jonak,William Damsky,Johannes Griss,Patrick M. Brunner
DOI: https://doi.org/10.1038/s41467-024-46540-0
IF: 16.6
2024-04-03
Nature Communications
Abstract:Dupilumab, an IL4R-blocking antibody, has shown clinical efficacy for atopic dermatitis (AD) treatment. In addition to conjunctivitis/blepharitis, the de novo appearance of head/neck dermatitis is now recognized as a distinct side effect, occurring in up to 10% of patients. Histopathological features distinct from AD suggest a drug effect, but exact underlying mechanisms remain unknown. We profiled punch biopsies from dupilumab-associated head and neck dermatitis (DAHND) by using single-cell RNA sequencing and compared data with untreated AD and healthy control skin. We show that dupilumab treatment was accompanied by normalization of IL-4/IL-13 downstream activity markers such as CCL13, CCL17 , CCL18 and CCL26 . By contrast, we found strong increases in type 22-associated markers ( IL22, AHR ) especially in oligoclonally expanded T cells, accompanied by enhanced keratinocyte activation and IL-22 receptor upregulation. Taken together, we demonstrate that dupilumab effectively dampens conventional type 2 inflammation in DAHND lesions, with concomitant hyperactivation of IL22 -associated responses.
multidisciplinary sciences
What problem does this paper attempt to address?
This paper aims to address a new side - effect issue that occurs when Dupilumab (an IL4R - blocking antibody) is used to treat atopic dermatitis (AD), namely Dupilumab - associated dermatitis of the head and neck (DAHND). Specifically, the study attempts to understand the mechanism of this newly emerging inflammatory response, especially its differences from traditional AD. ### Research Background Clinically, Dupilumab has been proven to have a significant effect on atopic dermatitis, but one of its side - effects is that the incidence of dermatitis of the head and neck is as high as 10%. Although the existence of this side - effect is known, its exact pathological mechanism remains unclear. Histopathological features suggest that this may be a drug effect, but the specific molecular and cellular mechanisms have not been identified. ### Main Problems The main problems that the paper attempts to solve are: - **What is the specific pathological mechanism of DAHND?** - **How does Dupilumab affect the immune response and lead to this special inflammatory phenotype?** ### Research Methods To answer these questions, researchers used single - cell RNA sequencing (scRNA - seq) technology to analyze skin biopsy samples from DAHND patients, untreated AD patients, and healthy controls. By comparing the cell types and gene expression patterns in these samples, the researchers hope to reveal the unique immune characteristics of DAHND. ### Main Findings 1. **Inhibition of Type 2 Inflammation**: Dupilumab treatment effectively inhibits the expression of traditional Type 2 inflammation markers (such as CCL13, CCL17, CCL18, and CCL26). 2. **Enhancement of Type 22 Inflammation**: Contrary to Type 2 inflammation, the researchers found that there is a significantly enhanced Type 22 inflammatory response in DAHND, especially an increase in the expression of markers such as IL22 and AHR, especially in oligoclonal - expanded T cells. 3. **Activation of Keratinocytes**: Keratinocytes in DAHND patients show strong IL - 22 - dependent activation, manifested as high - expression of genes such as S100A7, S100A8, and S100A9. 4. **Expansion of T - cell Clones**: A significant expansion of T - cell clones expressing IL22/IL13/AHR was observed in DAHND lesions, suggesting that these cells play a crucial role in disease development. 5. **Changes in Dendritic Cells**: Dendritic cells in DAHND show a reduction in Type 2 response, indicating that Dupilumab effectively blocks the IL - 4Rα signaling pathway in the tissue microenvironment. ### Conclusion Overall, this paper reveals the unique immune characteristics of DAHND that occur after Dupilumab treatment, especially the significant enhancement of Type 22 inflammation. These findings contribute to a better understanding of the pathological mechanism of DAHND and provide a theoretical basis for the future development of targeted treatment strategies. ### Formula Representation The formulas and symbols involved in the text are accurately presented in Markdown format: - Downstream activity markers of IL - 4/IL - 13: \[ \text{CCL13, CCL17, CCL18, CCL26} \] - Type 22 - related markers: \[ \text{IL22, AHR} \] - Keratinocyte activation markers: \[ \text{S100A7, S100A8, S100A9} \] These results emphasize the complexity of Dupilumab in regulating the immune response, especially the new problems that may occur when treating AD patients.